Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P. Wilson, Terry A. Jacobson, Peter H. Jones, et al.
Journal of clinical lipidology (2019) Vol. 13, Iss. 3, pp. 374-392
Closed Access | Times Cited: 424

Showing 1-25 of 424 citing articles:

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Florian Kronenberg, Samia Mora, Erik S.G. Stroes, et al.
European Heart Journal (2022) Vol. 43, Iss. 39, pp. 3925-3946
Open Access | Times Cited: 660
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Gissette Reyes‐Soffer, Henry N. Ginsberg, Lars Berglund, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2021) Vol. 42, Iss. 1
Open Access | Times Cited: 461
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease
Aniruddh P. Patel, Minxian Wang, James P. Pirruccello, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2020) Vol. 41, Iss. 1, pp. 465-474
Open Access | Times Cited: 305
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Michelle L. O’Donoghue, Robert S. Rosenson, Bariş Gencer, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 20, pp. 1855-1864
Open Access | Times Cited: 289
A Modern Approach to Dyslipidemia
Amanda J. Berberich, Robert A. Hegele
Endocrine Reviews (2021) Vol. 43, Iss. 4, pp. 611-653
Open Access | Times Cited: 283
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Ron C. Hoogeveen, Christie M. Ballantyne
Clinical Chemistry (2020) Vol. 67, Iss. 1, pp. 143-153
Open Access | Times Cited: 199
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary
Yehuda Handelsman, Paul S. Jellinger, Chris Guerin, et al.
Endocrine Practice (2020) Vol. 26, Iss. 10, pp. 1196-1224
Closed Access | Times Cited: 197
HEART UK consensus statement on Lipoprotein(a): A call to action
Jaimini Cegla, R. Dermot G. Neely, Michael France, et al.
Atherosclerosis (2019) Vol. 291, pp. 62-70
Open Access | Times Cited: 194
Lipoprotein(a) and its Significance in Cardiovascular Disease
Freddy Duarte Lau, Robert P. Giugliano
JAMA Cardiology (2022) Vol. 7, Iss. 7, pp. 760-760
Closed Access | Times Cited: 188
Lipoprotein(a) and Cardiovascular Disease
Pia R. Kamstrup
Clinical Chemistry (2020) Vol. 67, Iss. 1, pp. 154-166
Open Access | Times Cited: 174
Ten things to know about ten cardiovascular disease risk factors
Harold Bays, Pam R. Taub, Elizabeth Epstein, et al.
American Journal of Preventive Cardiology (2021) Vol. 5, pp. 100149-100149
Open Access | Times Cited: 169
Cardiovascular disease in diabetes, beyond glucose
Robert H. Eckel, Karin Bornfeldt, Ira J. Goldberg
Cell Metabolism (2021) Vol. 33, Iss. 8, pp. 1519-1545
Open Access | Times Cited: 135
Managing Atherosclerotic Cardiovascular Risk in Young Adults
Neil J. Stone, Sidney C. Smith, Carl E. Orringer, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 8, pp. 819-836
Open Access | Times Cited: 133
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, et al.
Archives of Medical Science (2021) Vol. 17, Iss. 6, pp. 1447-1547
Open Access | Times Cited: 132
Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk
Anurag Mehta, Nestor Vasquez, Colby Ayers, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 8, pp. 757-768
Open Access | Times Cited: 98
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 79
2023 Chinese guideline for lipid management
Jian‐Jun Li, Shui‐Ping Zhao, Dong Zhao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 69
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
Florian Kronenberg, Samia Mora, Erik S.G. Stroes, et al.
Atherosclerosis (2023) Vol. 374, pp. 107-120
Open Access | Times Cited: 54
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies
Waqas Malick, Sascha N. Goonewardena, Wolfgang Köenig, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 16, pp. 1633-1645
Open Access | Times Cited: 46
Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States
Harpreet Bhatia, Samantha Hurst, Paresh Desai, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 18
Open Access | Times Cited: 45
Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives
Pierandrea Vinci, Filippo Giorgio Di Girolamo, Emiliano Panizon, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 18, pp. 6721-6721
Open Access | Times Cited: 41
Lipoprotein(a) and cardiovascular disease
Børge G. Nordestgaard, Anne Langsted
The Lancet (2024)
Closed Access | Times Cited: 18
Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity
David M. Leistner, Andrés Laguna‐Fernandez, Arash Haghikia, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 7, pp. 856-865
Open Access | Times Cited: 17
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Gissette Reyes‐Soffer, Calvin Yeang, Erin D. Michos, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100651-100651
Open Access | Times Cited: 17
Prevention of Cardiovascular Disease in Type 1 Diabetes
Camila Manrique‐Acevedo, Irl B. Hirsch, Robert H. Eckel
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1207-1217
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top